MedWatch

Biomarin prepares for European approval of Ascendis competitor

US firm Biomarin has upgraded its financial expectations based on Q2, and is preparing a new drug that will challenge the existing market.

The EMA HQ in Amsterdam. | Photo: Rob Acket/EMA

US biotech firm Biomarin ended the second quarter with a revenue growth of 17 percent compared to the same period last year. The result was USD 501.7m.

Revenue for the first half year totaled USD 987.7m, a 6 percent increase compared to the first half of 2020.

Read the whole article

Get 14 days free access.
No credit card required.

An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP recommends nine new drugs, rejects one

Roche and Biogen are among the companies that have received recommendation for approval from the European Medicines Agency's committee (CHMP) at its September meeting. One Pfizer drug was the sole candidate to be rejected.

CEO at WSA: No clarity on EQT exit plans yet

The time horizon for the venture fund EQT's investment in WS Audiology should be ending soon, but according to Group CEO Eric Bernard, there is no clarity on when the potential changes might occur.

Further reading

Related articles

Trial banner

Latest news

See all jobs